+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Familial Adenomatous Polyposis (Genitourinary Disorders) - Drugs In Development, 2021

  • ID: 5359576
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 87 pages
  • Global Markets Direct

FEATURED COMPANIES

  • ADT Pharmaceuticals Inc
  • Cellix Bio Pvt Ltd
  • DNAlite Therapeutics Inc
  • Eloxx Pharmaceuticals Inc
  • Emtora Biosciences
  • FunPep Co Ltd
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis (Genitourinary Disorders) - Drugs In Development, 2021, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.

Familial adenomatous polyposis (FAP) or classic FAP is a genetic condition that causes extra tissue (polyps) to form in large intestine and rectum. It is caused by germline mutations in the APC gene. Symptoms include blood or mucus in the stools, diarrhea or constipation, weight loss due to unknown reason and abdominal pain. Treatment includes surgery and medications (NSAIDs).

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Familial Adenomatous Polyposis (Genitourinary Disorders) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 1, 4, 8, 1 and 1 respectively.

Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Adenomatous Polyposis (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Familial Adenomatous Polyposis (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Familial Adenomatous Polyposis (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • ADT Pharmaceuticals Inc
  • Cellix Bio Pvt Ltd
  • DNAlite Therapeutics Inc
  • Eloxx Pharmaceuticals Inc
  • Emtora Biosciences
  • FunPep Co Ltd
Introduction
  • Report Coverage
Familial Adenomatous Polyposis - Overview

Familial Adenomatous Polyposis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
Familial Adenomatous Polyposis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Familial Adenomatous Polyposis - Companies Involved in Therapeutics Development
  • ADT Pharmaceuticals Inc
  • Cancer Prevention Pharmaceuticals Inc
  • Cellix Bio Pvt Ltd
  • DNAlite Therapeutics Inc
  • Eloxx Pharmaceuticals Inc
  • Emtora Biosciences
  • FunPep Co Ltd
  • GLW Pharma
  • Johnson & Johnson
  • Recursion Pharmaceuticals Inc
  • SanaRx Biotherapeutics Inc
  • Stemsynergy Therapeutics Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • TherapyX Inc
  • Thetis Pharmaceuticals LLC
Familial Adenomatous Polyposis - Drug Profiles

(eflornithine hydrochloride + sulindac) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
CLXONC-57 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
FAPXIL SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Gene Therapy for Familial Adenomatous Polyposis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
guselkumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
icosapent ethyl - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
interleukin-10 SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
magnesium lysinate bis eicosapentaenoate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ombipepimut-s - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
pyrvinium pamoate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
REC-4881 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
SB-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
sirolimus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules for Colorectal Cancer and Familial Adenomatous Polyposis (FAP) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules for Familial Adenomatous Polyposis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit PDE10 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Synthetic peptide for Familial Adenomatous Polyposis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Familial Adenomatous Polyposis - Dormant Projects

Familial Adenomatous Polyposis - Discontinued Products

Familial Adenomatous Polyposis - Product Development Milestones

Featured News & Press Releases
  • Sep 11, 2020: Cancer Prevention Pharmaceuticals Announces NEJM publication of landmark phase 3 clinical trial for treatment of familial adenomatous polyposis
  • Jun 29, 2020: Cancer Prevention Pharmaceuticals submits New Drug Application to the FDA for CPP-1X/sul for treatment of familial adenomatous polyposis
  • Jun 18, 2020: Cancer Prevention Pharmaceuticals submits EU marketing authorization application for CPP-1X/sul for treatment of familial adenomatous polyposis
  • Apr 15, 2020: KD Pharma and SLA Pharma to study EPAspire for Covid-19
  • Nov 17, 2019: National Institute of Diabetes and Digestive and Kidney Diseases awards $2,073,687 SBIR fasttrack grant to Therapyx
  • Aug 26, 2019: Emtora Biosciences awarded $3 million CPRIT grant to study efficacy of eRapa in familial adenomatous polyposis
  • Aug 01, 2019: SLA Pharma announces meeting with the FDA in October 2019 for ALFA
  • Jun 20, 2019: Cancer Prevention Pharmaceuticals (CPP) reports FAP phase 3 clinical trial results at Digestive Disease Week Conference
  • May 07, 2019: Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt announce results from pivotal phase 3 trial of CPP-1X/Sulindac in patients with familial adenomatous polyposis
  • Apr 15, 2019: MorphoSys announces that its licensee Janssen has expanded clinical development of Guselkumab (Tremfya) into familial adenomatous polyposis
  • Feb 26, 2019: Rapamycin Holdings rebrands to Emtora Biosciences as new leadership focuses company on next steps
  • Dec 10, 2018: Cancer Prevention Pharmaceuticals Announces Last Patient Completes Phase 3 Trial Protocol of CPP-1X/sul for Familial Adenomatous Polyposis
  • Nov 19, 2018: Cancer Prevention Pharmaceuticals to present at Piper Jaffray Healthcare Conference in NYC, November 28, 2018
  • Oct 22, 2018: Marc L. Tokars Joins Cancer Prevention Pharmaceuticals as Vice President of Clinical and Regulatory Affairs
  • Feb 22, 2018: Cancer Prevention Pharmaceuticals Appoints Willene Brondum Associate Vice President of Regulatory Affairs and Quality Assurance
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development for Familial Adenomatous Polyposis, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Familial Adenomatous Polyposis - Pipeline by ADT Pharmaceuticals Inc, 2021
  • Familial Adenomatous Polyposis - Pipeline by Cancer Prevention Pharmaceuticals Inc, 2021
  • Familial Adenomatous Polyposis - Pipeline by Cellix Bio Pvt Ltd, 2021
  • Familial Adenomatous Polyposis - Pipeline by DNAlite Therapeutics Inc, 2021
  • Familial Adenomatous Polyposis - Pipeline by Eloxx Pharmaceuticals Inc, 2021
  • Familial Adenomatous Polyposis - Pipeline by Emtora Biosciences, 2021
  • Familial Adenomatous Polyposis - Pipeline by FunPep Co Ltd, 2021
  • Familial Adenomatous Polyposis - Pipeline by GLW Pharma, 2021
  • Familial Adenomatous Polyposis - Pipeline by Johnson & Johnson, 2021
  • Familial Adenomatous Polyposis - Pipeline by Recursion Pharmaceuticals Inc, 2021
  • Familial Adenomatous Polyposis - Pipeline by SanaRx Biotherapeutics Inc, 2021
  • Familial Adenomatous Polyposis - Pipeline by Stemsynergy Therapeutics Inc, 2021
  • Familial Adenomatous Polyposis - Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2021
  • Familial Adenomatous Polyposis - Pipeline by TherapyX Inc, 2021
  • Familial Adenomatous Polyposis - Pipeline by Thetis Pharmaceuticals LLC, 2021
  • Familial Adenomatous Polyposis - Dormant Projects, 2021
  • Familial Adenomatous Polyposis - Discontinued Products, 2021
List of Figures
  • Number of Products under Development for Familial Adenomatous Polyposis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
  • ADT Pharmaceuticals Inc
  • Cancer Prevention Pharmaceuticals Inc
  • Cellix Bio Pvt Ltd
  • DNAlite Therapeutics Inc
  • Eloxx Pharmaceuticals Inc
  • Emtora Biosciences
  • FunPep Co Ltd
  • GLW Pharma
  • Johnson & Johnson
  • Recursion Pharmaceuticals Inc
  • SanaRx Biotherapeutics Inc
  • Stemsynergy Therapeutics Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • TherapyX Inc
  • Thetis Pharmaceuticals LLC
Note: Product cover images may vary from those shown
Adroll
adroll